Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How ugly? I'm thinking you said you represent a long who is unhappy with NNVC. Apologies if I have that wrong. Are the answers ugly enough that the investor you represent is getting out?
Let's hope so, Scooby.
Completely agree. The case is laughable. And, don't get me wrong, I screw up grammar/punctuation with the best of them. However, I'd hope any lawyer on my payroll would meet a slightly higher standard. Not to mention I'd hope they'd actually navigate to the URLs from which data was culled.
Actually, your last statement is a negative. <head explodes>
If you ran a company and it was a scam, would you uplist to an exchange with more stringent listing requirements?
Beyond the astounding discovery and the brilliant research required to find it, that is one beautiful story.
Thank you for participating, DocFG. Your posts are just about the only reason I read this board. Keep bringing those meat filled posts while others keep bringing empty complaints and unwavering, uninformed opinions.
Really liking the implications here (thanks for sharing, L Vus!):
I used that conference call primarily to confirm my understanding of the press release. We strayed beyond that, but I've decided not to address topics outside the content of that press release, for a number of reasons.
First, the content of the press release is so historic, it's absurd to gild the lily. Second, it might trigger a requirement that the company file with the SEC regarding new public information. I don't want to force them to do that, yet.
Too funny. Why do I get the feeling the posters this is aimed at will read it and think to themselves, "Yes, finally someone gets it."
Appreciate it. You have a good weekend as well!
The most knowledgeable person on this board is also the most patient. Correlation or coincidence? Last I checked wisdom and patience were rather inextricable.
Piecemaker, I believe you intended to reply to the OP. You and I are in agreement.
>> 2. there exists a developing pattern of failure to delegate -
Exactly what part of the website buildout are you wanting them to delegate that they haven't already? The review before it goes live? I'd hope not.
Haha, well, walking and chewing are completely overrated anyway. Sitting and buying NNCV, on the other hand, completely underrated.
As an aside and totally off-topic, any chance CIGX is the Alzheimer's related stock in the Agora email posted earlier?
Ah, yes, we are saying the same thing albeit one of us is communicating at about a 200 IQ while the other sits right around 12. I'll leave it to you to figure out who's who.
I sure wish I knew; however, it's probably safe to say it's as close as the next Newsletter or company PR. :)
Hmm, if this were the case wouldn't Schwab consistently say shares are hard to come by for shorting? I'm leaning more towards the idea that these recent spikes attracted a larger quantity of shorts who have borrowed most of what's available.
Either way, would like to see these guys squeezed.
It'll neva end? Neva eva? I like the way you think, nanopatent.
Thanks for the info, m2m. Look at the data for 3/22 and what the stock did 3/23. Difficult to predict downward pressure; otherwise, we'd all be loaded. :)
The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour®”), to which the Company has licenses in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus, Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV),Hepatitis B Virus (HBV), and Rabies.
The Company has entered into an Additional License Agreement with TheraCour granting the Company the exclusive licenses in perpetuity for technologies developed by TheraCour for the additional virus types for Dengue viruses, Japanese Encephalitis, West Nile Virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes, and Ebola/Marburg viruses,.
A reverse split could take care of the share price requirement; although, I like the idea of something catapulting it higher much, much better.
For those that didn't watch the ~90 min Dr. Harris lecture here's a NYT Q and A from 2003 that pretty much captures what she's about:
http://www.nytimes.com/2003/09/30/science/conversation-with-eva-harris-simple-side-high-tech-makes-developing-world-better.html?pagewanted=2
Q. Within science nowadays, there's a trend where researchers own a piece of their discoveries and set up companies to market them. Could you ever see yourself doing that?
A. No. With my own lab research, which is partly on how the dengue fever virus replicates itself, I wouldn't want to own it. I don't think my research should be about my ego or financial success. From what I've seen this trend toward ownership makes the new discoveries inaccessible to most of the world because it contributes to raising their costs beyond what most people can afford.